Vyne Therapeutics Stock In The News
| VYNE Stock | USD 1.85 0.05 2.63% |
Our overall analysis of Vyne Therapeutics' news coverage and content from conventional and social sources shows investors' bearish mood towards Vyne Therapeutics. The specific impact of Vyne Therapeutics news on its stock price will depend on a range of factors, including the nature and significance of the news report and investors' perceptions of Vyne Therapeutics' overall financial health and prospects. It also depends on the type and quality of a news publisher.
Some academic researchers believe in a strong correlation between financial news and their impacts on the movements of stock prices. Macroaxis does not take a position on this subject and only provides tools that can help investors to time the market using Vyne Therapeutics headlines in addition to utilizing other, more conventional financial analysis modules. Check out Vyne Therapeutics Backtesting and Vyne Therapeutics Hype Analysis. For information on how to trade Vyne Stock refer to our How to Trade Vyne Stock guide.
Vyne |
Vyne Therapeutics Today Top News and Investor Outlook
Vyne Therapeutics Past News Timeline
Popular news outlets such as MarketWatch, Bloomberg, or Reuters provide Vyne and other traded companies coverage with news coverage. We help investors stay connected with Vyne headlines for the 15th of March 2025 to make an informed investment decision based on correlating the impacts of news items on Vyne Stock performance. Please note that trading solely based on the Vyne Therapeutics hype is not for everyone as timely availability and quick action are needed to avoid losses.
Vyne Therapeutics stock price changes are notoriously difficult to predict based exclusively on its news coverage or social hype. Still, the Vyne earnings-per-share ratio is a good starting point for gauging a company's future prospects. If a firm's EPS rises and meets or even beats consensus forecasts, its shares stand to increase. However, some very sophisticated investors can spot management manipulation of EPS through actions such as buybacks.
Far too much social signal, news, headlines, and media speculation about Vyne Therapeutics that are available to investors today. That information is available publicly through Vyne media outlets and privately through word of mouth or via Vyne internal channels. However, regardless of the origin, that massive amount of Vyne data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Vyne Therapeutics news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Vyne Therapeutics relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Vyne Therapeutics' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Vyne Therapeutics alpha.
Vyne Largest EPS Surprises
Earnings surprises can significantly impact Vyne Therapeutics' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2024-08-14 | 2024-06-30 | -0.19 | -0.22 | -0.03 | 15 | ||
2024-11-11 | 2024-09-30 | -0.23 | -0.29 | -0.06 | 26 | ||
2024-05-09 | 2024-03-31 | -0.24 | -0.15 | 0.09 | 37 | ||
2024-02-29 | 2023-12-31 | -0.5 | -0.2 | 0.3 | 60 | ||
2022-05-12 | 2022-03-31 | -2.97 | -2.52 | 0.45 | 15 | ||
2022-03-17 | 2021-12-31 | -4.26 | -3.6 | 0.66 | 15 |
Vyne Therapeutics Stock Latest Headlines
Some academic researchers believe in a strong correlation between financial news and their impacts on the movements of stock prices. Macroaxis does not take a position on this subject and only provides tools that can help investors to time the market using conventional financial analysis. Below is the latest headlines and news related to Vyne Therapeutics Stock. Current markets are strongly bullish. About 93% of major world exchanges and indexes are currently up. See today's market update for more information.
7th of March 2025
VYNE Therapeutics Receives Buy Rating from HC Wainwright at thelincolnianonline.com
6th of March 2025
VYNE Therapeutics Reports 2024 Fourth Quarter and Year-End Financial Results and Provides ... at gurufocus.com
4th of March 2025
Disposition of 1719 shares by Iain Stuart of Vyne Therapeutics at 0.223 subject to Rule 16... at MacroaxisInsider
19th of February 2025
VYNE Therapeutics Initiates Phase 1b Trial of VYN202, a Novel BD2-Selective Oral BET Inhib... at gurufocus.com
31st of January 2025
VYNE Therapeutics Inc. Short Interest Up 82.9 percent in January at thelincolnianonline.com
21st of January 2025
Acquisition by David Domzalski of 730000 shares of Vyne Therapeutics at 2.77 subject to Ru... at MacroaxisInsider
16th of January 2025
Vyne therapeutics director Patrick Lepore buys 43,800 in stock - Investing.com at news.google.com
7th of January 2025
Wainwright maintains buy on VYNE stock, cites clinical progress - Investing.com at news.google.com
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Vyne Therapeutics in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Vyne Therapeutics' short interest history, or implied volatility extrapolated from Vyne Therapeutics options trading.
Check out Vyne Therapeutics Backtesting and Vyne Therapeutics Hype Analysis. For information on how to trade Vyne Stock refer to our How to Trade Vyne Stock guide.You can also try the Equity Valuation module to check real value of public entities based on technical and fundamental data.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Vyne Therapeutics. If investors know Vyne will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Vyne Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share 1.72 | Revenue Per Share | Quarterly Revenue Growth 0.467 | Return On Assets | Return On Equity |
The market value of Vyne Therapeutics is measured differently than its book value, which is the value of Vyne that is recorded on the company's balance sheet. Investors also form their own opinion of Vyne Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Vyne Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Vyne Therapeutics' market value can be influenced by many factors that don't directly affect Vyne Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Vyne Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Vyne Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Vyne Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.